SCA
FOLD

Spearhead Capital Advisors’s Amicus Therapeutics FOLD Stock Holding History

Spearhead Capital Advisors’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-35,628
Closed -$412K – 209
2021
Q4 		$412K Buy
35,628
+2,237
+7% +$24.9K 0.05% 114
2021
Q3 		$319K Buy
33,391
+1,699
+5% +$17.4K 0.04% 145
2021
Q2 		$306K Buy
31,692
+6,555
+26% +$64K 0.04% 177
2021
Q1 		$248K Buy
+25,137
New +$389K 0.04% 179

Other funds holding FOLD

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Spearhead Capital Advisors's FOLD Position: Q1 2022 in Review

Spearhead Capital Advisors sold out of Amicus Therapeutics (FOLD) in Q1 2022, closing a stake of 35,628 shares — an estimated $412K sold.

Spearhead Capital Advisors first reported a position in FOLD in Q1 2021 and held it in 4 quarters. The position peaked at $412K in Q4 2021. 217 funds tracked by Wall St. Rank hold FOLD as of Q1 2022.

  • Spearhead Capital Advisors reported no remaining Amicus Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Spearhead Capital Advisors sold 35,628 Amicus Therapeutics shares in Q1 2022, an estimated $412K.
  • Spearhead Capital Advisors first reported a position in Amicus Therapeutics in Q1 2021 and held it in 4 quarters.
  • Spearhead Capital Advisors's Amicus Therapeutics position peaked at $412K in Q4 2021.
  • 217 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2022.

Based on Spearhead Capital Advisors's 13F filing for Q1 2022, filed 28 Apr 2022.